FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

All subjects completed the trial per protocol, no safety concerns found up to the highest dose tested of 2400 mg/day
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201. This single-site study was conducted at the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia and enrolled 48 healthy adult men and women. read more

FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the “Company”) announces the closing of a previously announced private placement of 1,500,000 of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share and warrants to purchase 1,500,000 Shares (cumulatively, the “Securities”) of the Company to certain institutional investors for gross proceeds, before deducting placement fees and other estimated offering expenses payable by the Company, of approximately C$10.125 million. The warrants have a five-year term and an exercise price of C$9.65 per share. read more

FSD Pharma Inc. Announces C$10.125 Million Private Placement

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) CSE;HUGE or the “Company”), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million. The Company has also agreed to issue common share purchase warrants to purchase 1,500,000 Shares of the Company. The warrants will have a five year-term and an exercise price of C$9.65 per share. The closing of the offering is expected to occur on or about June 8, 2020, subject to the satisfaction of customary closing conditions including applicable exchange approvals.  The Company has granted the investors an option to acquire up to an additional C$10.125 million of units on the terms set forth above for a period of 30 days following the initial closing. read more

FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients. read more

FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia, to initiate a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of ultra-micronized-PEA in normal healthy volunteers. read more

FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday, March 6, 2020

– Reports audited financial results for the Fourth Quarter and Full Year ended December 31, 2019 –
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that Executive Co-Chairman and CEO, Raza Bokhari, MD will be joined by the Company’s founders, Anthony Durkacz and Zeeshan Saeed, members of its Board of Directors, and leadership team to ring the opening bell at the Canadian Securities Exchange (CSE) on Friday, March 6, 2020 at 9:30 a.m. Eastern time. read more

FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced the sale of its 12% equity interest in Cannara Biotech Inc. (CSE: LOVE) (“Cannara”) to a consortium of buyers for cash proceeds of more than $7.7 million (the “Share Sale Transaction”). read more

FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, accompanied by FSD Pharma Biosciences leadership, will be participating in the 22nd Annual BIO CEO & Investor conference, including presenting a company overview at 9:45 a.m. ET on Monday, February 10, 2020. read more

FSD Pharma and Solarvest Enhance Commitment to CBD Research Project

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest”) (collectively, the “Parties”), are pleased to announce that, further to their press release of May 7, 2019, the Parties have agreed to amendments to the Collaborative Research and Development Agreement (the “Research Agreement”) designed to accelerate progress of the research project that Solarvest is carrying out (the “CBD Research Project”). Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares (“FSD Shares”) to Solarvest, which will enable Solarvest to fund the CBD Research Project. In addition, Solarvest has appointed Dr. Edward J. Brennan, Jr., M.D., FACS (“Dr. Brennan”), currently the President of FSD Pharma’s BioSciences Division, to the board of directors of Solarvest. read more